A Case of Bullous Pemphigoid Arising after Infliximab Therapy in a Patient with Rheumatoid Arthritis.
10.4078/jkra.2010.17.4.422
- Author:
Seong Oh PARK
1
;
Ji Hyun LEE
Author Information
1. Department of Rheumatology, Maryknoll Hospital, Busan, Korea. ete@lycos.co.kr
- Publication Type:Case Report
- Keywords:
Infliximab;
Bullous pemphigoid;
Rheumatoid arthritis
- MeSH:
Aged;
Antibodies, Monoclonal;
Arthritis, Rheumatoid;
Basement Membrane;
Blister;
Captopril;
Complement C3;
Female;
Furosemide;
Humans;
Infliximab;
Immunoglobulins;
Middle Aged;
Pemphigoid, Bullous;
Penicillamine;
Penicillins;
Prevalence;
Skin Diseases, Vesiculobullous;
Sulfasalazine
- From:The Journal of the Korean Rheumatism Association
2010;17(4):422-425
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bullous pemphigoid is an autoimmune, subepidermal blistering disease commonly seen in the elderly. It is known as autoimmune bullous dermatoses with an estimated prevalence of 1 in 40,000 and shows no gender or racial predilection. It has an autoimmune nature with immunoglobulin (Ig) G and/or C3 complement targeting hemidesmosomal antigens located in the epidermal basement membrane zone. Drug-induced pemphigoid, although rare, can occur in patients taking penicillamine, furosemide, captopril, penicillin, or sulfasalazine, but infliximab-induced pemphigoid has not been reported. We experienced a case of infliximab-induced pemphigoid in 54-year-old woman with a 17-year history of rheumatoid arthritis.
